Fatal pneumonitis induced by oxaliplatin

Clinical and Translational Oncology

Volumn 10, Issue 11, 2008, Pages 764-767

  Lobera, Sara Arévalo ^a   Mariñelarena, Naiara Sagastibeltza ^a   Echeberría, Ibone Elejoste ^a   Olivé, Mireia Melé ^a   Otaño, Larraitz Egaña ^a   Badiola, Laura Basterretxea ^a   La Casta Muñoa, Adelaida ^a   Gabilondo, Mikel Azkue ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

Oxaliplatin; Pneumonitis; Pulmonary fibrosis; Pulmonary toxicity; Respiratory failure

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLFOX PROTOCOL; FOLINIC ACID; OXALIPLATIN; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; COLON TUMOR; COMPUTER ASSISTED TOMOGRAPHY; FATALITY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS; LUNG FIBROSIS; LUNG RESECTION; LUNG TUMOR; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSTOPERATIVE COMPLICATION; RADIOGRAPHY; WEGENER GRANULOMATOSIS;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FATAL OUTCOME; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; ORGANOPLATINUM COMPOUNDS; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; PULMONARY ALVEOLI; PULMONARY FIBROSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; SIGMOID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WEGENER GRANULOMATOSIS;

EID: 59249088649     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0285-7     Document Type: Article

References (13)

1. Raymond E, Faivre S, Chaney S et al (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235
2. André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
3. Ramanathan RK, Clark JW, Kemeny NE et al (2003) Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 15:2904-2911
4. Hausheer F, Schilsky R, Bain S et al (2006) Diagnosis, management and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15-49
5. Anonymous (2006) Peripheral neuropathy induced by oxaliplatin-based chemotherapy. J Support Oncol 4:82-83
6. Patelli M, Falcone F, Poletti V (2001) Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J 1:243-245
7. Pasetto LM, Monfardini S (2006) Is acute dyspnea related to oxaliplatin administration? Worl J Gastroenterol 12:5907-5908
8. Garrido M, O'Brien A, González S et al (2007) Cryptogenetic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest 132:1997-1999
9. Yagüe XH, Soy E, Marino BQ et al (2006) Interstitial pneumonitis alter oxaliplatin treatment in colorrectal cancer. Clin Transl Oncol 8:624
10. Gagnadoux F, Roiron C, Carrie E et al (2002) Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 25:388-390
11. Wilcox BE, Ryu JH, Kalra S (2008) Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med 102:273-279
12. Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with me-tastatic colorectal cancer. Ann Oncol 15:460-466
13. Kinnula VL, Vuorinen K, Ilumets H et al (2007) Thiol proteins, redox modulation and parenchymal lung disease. Curr Med Chem 14:213-222